Pembrolizumab Approved for Children and Adults with Hard-to-Treat Hodgkin Lymphoma March 15, 2017December 14, 2022 Arthur N. Brodsky, PhD
Pembrolizumab (Keytruda®) Approved as First-Line Option for Lung Cancer October 25, 2016December 14, 2022 Arthur N. Brodsky, PhD
FDA Approves Another Immunotherapy Option for Patients with Advanced Lung Cancer October 18, 2016December 14, 2022 Arthur N. Brodsky, PhD
FDA Approves Pembrolizumab (Keytruda®), a PD-1 Antibody, for Head and Neck Cancer August 8, 2016December 14, 2022 Alexandra Mulvey
Atezolizumab (Tecentriq™) Receives FDA Approval for Bladder Cancer May 19, 2016December 14, 2022 Arthur N. Brodsky, PhD
FDA Approves Nivolumab (Opdivo) for Advanced Hodgkin Lymphoma Patients May 17, 2016December 14, 2022 Arthur N. Brodsky, PhD
